secwatch.observer — SEC 8-K summary
======================================

Issuer:     AEON Biopharma, Inc. (AEON)
CIK:        0001837607
Form:       8-K
Filed at:   2024-03-29T23:59:59+00:00
Accession:  0001837607-24-000013
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AEON Biopharma reports FY 2023 results; aligns with FDA on Phase 3 migraine design
--------------------------------------------------------------------------------

- End-of-Phase 2 meeting with FDA achieved alignment on pivotal Phase 3 trial design for episodic and chronic migraine.
- Phase 2 chronic migraine study completed enrollment (492 patients); interim analysis data expected Q2 2024.
- Announced $15M private placement of senior secured convertible notes with Daewoong; first $5M closed, second $10M due April 2024.
- Cash runway projected through June 2024 only; company to fund late-stage clinical development.
- No financial results provided in press release beyond qualitative business update.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1837607/000183760724000013/0001837607-24-000013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1837607/000183760724000013/aeon-20240329x8k.htm
  HTML page:      https://secwatch.observer/filing/0001837607-24-000013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer